Liz Lynn

Former molecular parasitologist, now supporting pharmacovigilance and pharmacoepidemiology

[Drug Safety Research @DSRUDrugSafety]

.@SaadShakirDSRU has written to new Health Secretary @theresecoffey to urge the UK government to facilitate use of #Evusheld to protect the clinically vulnerable against COVID-19, following approval of the drug by MHRA in March. https://t.co/11C08eyYQb @DHSCgovuk

[Liz Lynn @LizVLynn]

Have you had your booster #COVID19 vaccine in the past 2 days? If so, please sign up to take part in the Covid Vaccine Monitor study, an online questionnaire study monitoring for side effects. https://t.co/hxgFbj48WV #pharmacovigilance #COVIDVaccination

[Jabeen Ahmad 💙 @jabeenahmad01]

How the British Indian diaspora are rallying to help India's covid crisis. Doctors providing telemedicine consultations, fundraising for oxygen. So many UK folks with family in India are affected. Solidarity x
https://t.co/vONKvFS87V

[Liz Lynn @LizVLynn]

We’re using active surveillance to monitor the safety of @AstraZeneca #COVID19 vaccine in the UK population. Want to take part in this online questionnaire study? You can express your interest before or after your vaccination via this link: https://t.co/JjcrohQstb #COVIDvaccine

[Drug Safety Research @DSRUDrugSafety]

Our systematic benefit-risk assessment of #remdesivir suggests a favourable benefit-risk profile for #COVID19 patients with severe infection, based on limited data. Evaluation will be updated as more data becomes available https://t.co/Vc6wA3LD4u

[Drug Safety Research @DSRUDrugSafety]

Report @PJOnline_News on our paper @BMJ_EBM on a systematic benefit-risk assessment for buprenorphine implant. A semi-quantitative method used to support risk management. https://t.co/T2gOLEPOtc More on #BenefitRisk: https://t.co/VoFrzUUPrb

[Drug Safety Research @DSRUDrugSafety]

A cytokine storm is an uncontrollable flood of cytokines which tends to worsen respiratory function and lead to multi-organ failure, and is thought to be a potential cause of death of COVID-19 patients. See the blog by @SaadShakirDSRU for explanation: https://t.co/90RAvbto4G

[Drug Safety Research @DSRUDrugSafety]

Cytokine storms are a major killer in patients with severe #COVID19 infection. Read the new blog by @SaadShakirDSRU which covers the effect of a #CytokineStorm on the body and the treatment options https://t.co/90RAvbto4G

[Drug Safety Research @DSRUDrugSafety]

How will #Pharmacovigilance need to evolve in order to handle the challenges posed by scientific innovation and political upheaval? Read interview with our Director @SaadShakirDSRU in the March edition of @Pharmafocus https://t.co/TguoOSPzbz

[Liz Lynn @LizVLynn]

@vlo_25 You're welcome 🙂

[Mara Gordon, MD @MaraGordonMD]

Twins are both treated for breast cancer. One in the US, one in the UK.

"Nora was able to confront many of these issues without worrying about a mounting pile of bills.. Nancy’s primary attention was focused on managing the complex financial issues.."

https://t.co/16rW1zgL7L

[Drug Safety Research @DSRUDrugSafety]

Detection of adverse drug reactions (ADRs) is built into regulatory requirements for new drugs. One aim of Post-Authorisation Safety Studies (PASS) is to identify, characterise or quantify a safety hazard https://t.co/T6zVO8sEcn https://t.co/N9LCLKvi95

[Drug Safety Research @DSRUDrugSafety]

Outsource your #pharmacoepidemiology to DSRU Consulting! We provide a special price-capped service for smaller companies. Benefit from our decades of experience and expertise of our multidisciplinary consultancy team. #Pharmacovigilance https://t.co/pnJhB0PEaB

[Drug Safety Research @DSRUDrugSafety]

Don't miss our first course on Devices Vigilance next month! We'll address the interpretation, challenges and practical implications of the new #MedicalDevice Regulations #EUMDR which will be implemented in May https://t.co/Vy98L9QUmd #meddevice #medtech #medicaldevices

[Drug Safety Research @DSRUDrugSafety]

DSRU Consultancy provides a special price-capped package for smaller companies. Our expert team provides one-off or ongoing advice on #Pharmacovigilance #pharmacoepi risk minimisation & risk management. World class science at a not for profit price! https://t.co/pnJhB0PEaB

[Drug Safety Research @DSRUDrugSafety]

Are you a pharmacist who wants to know more about #Pharmacovigilance? One week to go until our first joint courses with @rpharms. Find out about pharmacovigilance and how #pharmacists are involved at our interactive course. Great speakers!

[Drug Safety Research @DSRUDrugSafety]

A great turn out for our GP Masterclass in Effective Prescribing @RCGP today. Enlightening talk from GP Klaus Green, bringing to life drugs for #type2diabetes #GeneralPractice https://t.co/yQXgSAvXxD

[Drug Safety Research @DSRUDrugSafety]

Are you a pharmacist who's thinking of a career in drug safety? Join us on 18 November for our exciting new course with @rpharms to find out what it’s like to work in pharma https://t.co/e3QMwlymBq #Drugsafety #Pharmacovigilance #Careers #pharmacists

[Drug Safety Research @DSRUDrugSafety]

We’re well known for collecting real-world study data directly from prescribers, but #DYK we also do studies using #CPRD data? Examples include studies for PASS, pre-authorisation applications, drug utilisation etc See our case studies: https://t.co/uGQe5z54PH #Pharmacovigilance

[Drug Safety Research @DSRUDrugSafety]

Are you a #Pharmacist who wants to know more about #Pharmacovigilance? Join us on 18 November for our exciting new course with @rpharms to find out what pharmacovigilance is and how pharmacists can be involved. https://t.co/a66CDFoNOY #Drugsafety #pharmacists